SECONDARY MYELOFIBROSIS
Clinical trials for SECONDARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for SECONDARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo may reduce deadly transplant complication in blood cancer patients
Disease control CompletedThis study tested whether adding the drug itacitinib to the usual two-drug regimen (tacrolimus and sirolimus) could better prevent graft-versus-host disease (GVHD) in 59 adults with blood cancers (acute leukemia, myelodysplastic syndrome, or myelofibrosis) undergoing a donor stem…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New combo therapy shows promise for rare bone marrow cancer
Disease control CompletedThis study looked at whether giving a JAK inhibitor drug before a donor stem cell transplant helps people with myelofibrosis, a serious bone marrow disorder. The treatment aims to reduce symptoms like an enlarged spleen and inflammation, and improve survival after transplant. 61 …
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo therapy offers hope for myelofibrosis patients who failed standard care
Disease control CompletedThis study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis whose disease did not respond well to standard JAK-inhibitor therapy. The goal was to see if the combo could shrink the spleen, improve symptoms, or reduce the need for blood t…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 19, 2026 11:48 UTC